Brentuximab vedotin is under clinical development by Pfizer and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Brentuximab vedotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brentuximab vedotin overview

Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is formulated as a lyophilized powder for solution, solution for intravenous route of administration. Brentuximab vedotin is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. It is indicated for the treatment of patients with Classical HL at high risk of relapse or progression as post-auto-HSCT consolidation. It is also indicated for the treatment of patients with Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma.


Adcetris is under development for treatment of relapsed or refractory metastatic squamous or nonsquamous non-small cell lung cancer, head and neck cancer squamous cell carcinoma, metastatic cutaneous melanoma, relapsed and refractory follicular lymphoma, systemic mastocytosis and mast cell leukemia, relapsed CD30-positive cutaneous peripheral T-cell lymphoma including non systemic anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract, follicular T-cell lymphoma and nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype, non-Hodgkin lymphoma (NHL), third line therapy in diffuse large b-cell lymphoma (DLBCL), T-cell lymphomas, relapsed or refractory metastatic solid tumors and for the retreatment of adult patients with who previously responded to ADCETRIS and who later relapse, adult T-cell leukemia/lymphoma. It is under development for CD30-positive malignancies other than lymphoma, multiple myeloma, acute Graft vs. Host Disease (GvHD), relapsed and refractory peripheral T-cell lymphoma, lymphomatoid papulosis (LyP), CD30-positive primary cutaneous anaplastic large T-cell lymphoma (pc-ALCL), Hodgkin's lymphoma relapsed non-Hodgkin lymphoma, other lymphomas and CD30+ Hodgkin lymphoma, and it is indicated in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, and for the treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine). Adcetris is also indicated in combination with CHP (cyclophosphamide, doxorubicin, prednisone) chemotherapy for the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30.

It is under development for the treatment of malignant mesothelioma, Sezary syndrome and diffuse cutaneous systemic sclerosis. It was also under development for the treatment of testicular germ-cell cancer, relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) and systemic lupus erythematosus. Acute myelocytic leukemia, diffuse large B-Cell lymphoma and follicular Lymphoma and acute lymphoid leukemia, acute myeloid leukemia and mycosis fungoides and primary mediastinal B-cell lymphoma.

It was also under development for the treatment of human immunodeficiency virus (HIV) infections.

Pfizer overview

Pfizer discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

For a complete picture of Brentuximab vedotin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 January 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.